#1 Clinical Trials Search in Europe

Tozinameran

This article examines the use of Tozinameran, a key component in COVID-19 mRNA vaccines, in various clinical trials. These studies aim to assess the vaccine’s effectiveness, safety, and immune response in different populations and when administered alongside other vaccines. The research provides valuable insights into COVID-19 vaccination strategies and their impact on public health.

Table of Contents

What is Tozinameran?

Tozinameran, also known by its brand name Comirnaty, is a COVID-19 mRNA vaccine developed by BioNTech and Pfizer. It is designed to prevent infection from the SARS-CoV-2 virus, which causes COVID-19 disease[1]. This vaccine has been authorized for use in many countries worldwide and has played a crucial role in combating the COVID-19 pandemic.

Tozinameran is also known by several other names, including:

  • BNT162b2
  • Nucleoside-modified mRNA encoding a modified version of the SARS-CoV-2 S protein
  • Single-stranded, 5′-capped messenger RNA produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2

How Tozinameran Works

Tozinameran is an mRNA vaccine, which uses a novel approach to immunization. Here’s how it works:

  1. The vaccine contains mRNA (messenger RNA) that encodes the spike protein of the SARS-CoV-2 virus.
  2. When injected, the mRNA enters the body’s cells and instructs them to produce copies of the spike protein.
  3. The immune system recognizes these spike proteins as foreign and mounts an immune response, producing antibodies and T-cells.
  4. If the vaccinated person is later exposed to the actual SARS-CoV-2 virus, their immune system is primed to recognize and fight off the infection quickly.

This innovative approach allows the body to produce an immune response without being exposed to the live virus[1].

Effectiveness

Clinical trials and real-world studies have shown Tozinameran to be highly effective in preventing COVID-19 infection, particularly severe cases leading to hospitalization and death. The vaccine’s effectiveness has been demonstrated against various SARS-CoV-2 variants, although the level of protection may vary depending on the specific variant[2].

Administration

Tozinameran is typically administered as an intramuscular injection. The standard dosing regimen involves two doses, usually given 21 days apart. However, some studies are investigating different dosing schedules and the potential need for booster doses[3].

The vaccine is available in different formulations, including:

  • Comirnaty 30 micrograms/dose concentrate for dispersion for injection
  • Comirnaty Omicron XBB.1.5 30 micrograms/dose dispersion for injection
  • Comirnaty Omicron XBB.1.5 3 micrograms/dose concentrate for dispersion for injection (for pediatric use)

Safety and Side Effects

Tozinameran has undergone rigorous safety testing and continues to be monitored in ongoing studies. Common side effects include:

  • Pain and swelling at the injection site
  • Fatigue
  • Headache
  • Muscle pain
  • Chills
  • Fever

These side effects are generally mild to moderate and resolve within a few days. Serious adverse events are rare but can include allergic reactions[4].

Special Populations

Tozinameran has been studied in various populations, including:

  • Older adults: The vaccine has shown effectiveness in adults aged 65 and older, who are at higher risk for severe COVID-19[5].
  • Children and adolescents: Specific formulations have been developed for pediatric use, with ongoing studies to determine optimal dosing and safety profiles[3].
  • Immunocompromised individuals: Research is ongoing to assess the vaccine’s effectiveness and potential need for additional doses in this population[2].

Ongoing Research

Several clinical trials are currently underway to further investigate various aspects of Tozinameran, including:

  • Co-administration with other vaccines, such as influenza vaccines[6].
  • Effectiveness against new SARS-CoV-2 variants[4].
  • Long-term immunity and the potential need for booster doses[5].
  • Use in specific populations, such as pregnant women and individuals with certain medical conditions[7].

These ongoing studies will continue to provide valuable information about the vaccine’s safety, efficacy, and optimal use in various populations and scenarios.

Aspect Details
Study Types Phase 2, Phase 3, and Phase 4 clinical trials
Primary Objectives Assess safety, immunogenicity, and efficacy of Tozinameran-containing vaccines
Key Populations Adults 18+, with focus on 50+ and 65+ in some trials
Main Outcome Measures Neutralizing antibody levels, binding antibody levels, T-cell responses
Safety Monitoring Local and systemic reactions, adverse events, serious adverse events
Special Considerations Co-administration with flu vaccines, different dosing schedules, various administration methods
Duration Varies by study, ranging from weeks to several months

FAQ

  • What is Tozinameran? Tozinameran is the active ingredient in some COVID-19 mRNA vaccines, such as Comirnaty. It's a nucleoside-modified mRNA that encodes a modified version of the SARS-CoV-2 spike protein, helping the body develop immunity against the virus.
  • What are the main objectives of these clinical trials? The main objectives include assessing the safety and efficacy of Tozinameran-containing vaccines, evaluating immune responses in different age groups, studying the effects of co-administration with other vaccines (like flu shots), and investigating the impact of different dosing schedules and administration methods.
  • Who are the typical participants in these trials? Participants vary by study but generally include adults aged 18 and older, with some trials focusing on specific groups like those 50 or 65 and above. Some studies also include individuals with certain medical conditions or those who have previously received COVID-19 vaccines or treatments.
  • How is the effectiveness of the vaccine measured in these trials? Effectiveness is primarily measured through immune response indicators such as neutralizing antibody levels, binding antibody levels, and T-cell responses. Some trials also track the incidence of COVID-19 cases among participants.
  • What safety aspects are being monitored in these clinical trials? Safety monitoring includes tracking solicited local and systemic reactions, unsolicited adverse events, serious adverse events, and any events of special interest. Some trials also monitor for specific conditions like myocarditis or changes in laboratory parameters.

Ongoing Clinical Trials on Tozinameran

  • Study on Immune Response in COVID-19 Recovered Patients Treated with Monoclonal Antibodies: Effects of Revaccination with Elasomeran, Tozinameran, and Cilgavimab

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    Italy

  • Study on Immune Responses to COVID-19 Vaccines: Raxtozinameran, Bretovameran, and Drug Combination for COVID-19 Patients

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Finland

  • Study on Intradermal COVID-19 mRNA Vaccine (Tozinameran, Famtozinameran) for Elderly Patients Aged 75 and Older

    Not recruiting

    2 1 1 1
    Investigated drugs:
    The Netherlands

  • Study on the Immune Response of COVID-19 Vaccine Tozinameran with Flu Vaccine Combinations in Adults Aged 65 and Over

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium The Netherlands

Glossary

  • Tozinameran: The active substance in some COVID-19 mRNA vaccines, consisting of a modified mRNA that encodes the SARS-CoV-2 spike protein.
  • mRNA vaccine: A type of vaccine that uses a copy of a molecule called messenger RNA (mRNA) to produce an immune response, teaching cells how to make a protein that triggers an immune response inside our bodies.
  • Neutralizing antibodies: Antibodies that defend cells from pathogens or infectious particles by neutralizing their biological effects.
  • T-cell response: A part of the immune response involving T lymphocytes, which play a crucial role in cell-mediated immunity.
  • Immunogenicity: The ability of a substance, such as a vaccine, to provoke an immune response in the body.
  • Adverse event: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Geometric Mean Titer (GMT): A way of expressing antibody levels in a group of test subjects as an average.
  • Pseudovirus neutralization assay: A laboratory test used to measure the ability of antibodies to neutralize a virus, using a modified virus that mimics the target virus but is safer to handle.
  • Monoclonal antibodies: Laboratory-produced molecules engineered to serve as substitute antibodies that can restore, enhance, or mimic the immune system's attack on cells.
  • Adjuvant: A substance added to a vaccine to enhance the body's immune response to the vaccine.

References

  1. http://clinicaltrials.eu/trial-id/2023-503800-99-00
  2. http://clinicaltrials.eu/trial-id/2023-503894-39-00
  3. http://clinicaltrials.eu/trial-id/2023-507348-35-00
  4. http://clinicaltrials.eu/trial-id/2023-508458-25-00
  5. http://clinicaltrials.eu/trial-id/2023-510196-59-00
  6. http://clinicaltrials.eu/trial-id/2024-514798-23-00
  7. http://clinicaltrials.eu/trial/study-on-immune-response-in-covid-19-recovered-patients-treated-with-monoclonal-antibodies-effects-of-revaccination-with-elasomeran-tozinameran-and-cilgavimab/